STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase I/II Clinical Trial
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)
Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Endometrial Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer, Ovarian Cancer
Trial Number: 04585750
Trial Status: OPEN